• Sadik Z H A ZHA Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Nethe, Voormolen E H J EHJ Department of Neurosurgery, Utrecht University Medical Center, Utrecht, The Netherlands., Depauw P R A M PRAM Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands., B Burhani, W A Nieuwlaat, J Verheul, S Leenstra, R Fleischeuer, and Hanssens P E J PEJ Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands..
• Gamma Knife Center, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Elisabeth-Tweesteden Hospital, Tilburg, The Netherlands; Department of Neurosurgery, Utrecht University Medical Center, Utrecht, The Netherlands. Electronic address: z.sadik@etz.nl.
• World Neurosurg. 2017 Apr 1; 100: 361-368.

ObjectiveIt is still not clear whether Gamma Knife radiosurgery (GKRS) for nonfunctional pituitary adenomas should be used as a standard adjuvant postoperative therapy or applied when there is documented progression of the remnant on follow-up magnetic resonance imaging.MethodsWe performed a retrospective study of patients with nonfunctional pituitary adenomas who underwent primary surgery and GKRS between 2002 and 2015. Patients were divided into 2 groups on the basis of the GKRS indication: adjuvant treatment (GKRS ≤6 months postoperatively) or delayed treatment (GKRS if documented progression occurred on the follow-up magnetic resonance imaging).ResultsFifty patients were included and grouped based on adjuvant (n = 13) or delayed (n = 37) GKRS following primary surgery. The adjuvant and delayed groups had 10-year actuarial tumor control rates of 92% and 96% (P = 0.408), respectively. The 10-year actuarial endocrinologic control rate was 82% for the adjuvant group and 49% for the delayed group (P = 0.597). None of the patients developed any new neurologic deficit post-GKRS. GKRS-induced complications (intratumoral bleeding and tumoral tissue inflammation) occurred in 6% of the patients, of whom 4% were in the delayed group and 2% in the adjuvant group.ConclusionAdjuvant treatment with GKRS yields the same high long-term tumor control as delayed GKRS. Neither adjuvant nor delayed GKRS induced additional neurologic complications. There is a trend that adjuvant GKRS induces less additional endocrinologic deficits compared with delayed GKRS.Copyright © 2017 Elsevier Inc. All rights reserved.

30 keywords...

hide…